Baseline clinical characteristics
| Variable | Total population (n=100) |
|---|---|
| Patient characteristics | |
| Age, years | 69.5±9.5 |
| Male, n (%) | 68 (68) |
| Diabetes mellitus, n (%) | 40 (40) |
| Hypertension, n (%) | 79 (79) |
| Systolic blood pressure, mm Hg | 132±14 |
| Dyslipidaemia, n (%) | 77 (77) |
| HDL-cholesterol, mg/dL | 53±14 |
| Chronic kidney disease stage | 2.1±0.65 |
| Current Smoker, n (%) | 24 (24) |
| Peripheral artery disease, n (%) | 9 (9) |
| History of stroke or transient ischaemic attack, n (%) | 5 (5) |
| History of percutaneous coronary intervention, n (%) | 23 (23) |
| History of myocardial infarction, n (%) | 7 (7) |
| Angina, n (%) | |
| Asymptomatic | 31 (31) |
| CCS class I | 32 (32) |
| CCS class II | 26 (26) |
| CCS class III | 11 (11) |
| Ejection fraction (%) | 70.8±7.0 |
| Left ventricular hypertrophy, n (%) | 28 (28) |
| Brain natriuretic peptide, pg/mL | 26.1 [15.9–48.4] |
| C reactive protein, mg/L | 1.2 [0.5–3.4] |
| ARB or ACEI, n (%) | 50 (50) |
| β-blocker, n (%) | 20 (20) |
| Calcium channel blocker, n (%) | 47 (47) |
| Statins, n (%) | 78 (78) |
Values are mean±SD or median [IQR] or number (percentage of total).
ARB, angiotensin II type 1 receptor antagonists; CCS, Canadian Cardiovascular Society; HDL, high-density lipoprotein.